DelveInsight’s “Waldenstrom’s Macroglobulinaemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Waldenstrom’s Macroglobulinaemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Waldenstrom’s Macroglobulinaemia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Waldenstrom’s Macroglobulinaemia: An Overview
According to the National Organization for Rare Disorders (NORD), Waldenstrom Macroglobulinemia (WM) is a rare indolent (slow-growing) B-cell lymphoma that occurs in <2% of patients with Non-Hodgkin’s Lymphoma (NHL). It is sometimes referred to as a lymphoplasmacytic lymphoma (LPL) with an associated monoclonal IgM paraprotein. This low-grade LPL usually affects older adults and generally involves the bone marrow, but it can also occur in the lymph nodes and other tissues and organs of the lymphatic system.
The affected cells over-produce an antibody of a specific class called IgM. The main characteristic of Waldenstrom’s Macroglobulinaemia is the overproduction of a monoclonal protein called “immunoglobulin M” (IgM). High protein levels called immunoglobulin M (IgM) might induce blood hyperviscosity and damage organs like the liver and spleen.
Waldenstrom’s Macroglobulinaemia Market Key Facts
The total Incident population of Waldenstrom macroglobulinemia (WM) in the 7MM was estimated to be more than 3,000+ in 2020.
The market size of Waldenstrom Macroglobulinemia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan was found to be more than USD 130 million in 2020.
According to a US SEER surveillance study on Waldenstrom’s Macroglobulinaemia, the incidence in the US was 0.3 per 100,000 population, and the median age at diagnosis was 73.
In 2020, Japan had an incidence of about 340 cases, out of which around 250 were males. The highest cases were of the age group above 65 years.
Among the 7MM, Spain had the lowest incidence cases of WM (~150 cases) in 2020.
MYD88 had the highest incidence among gene mutations in the US, with more than 1,000 cases in 2020.
Waldenstrom’s Macroglobulinaemia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Waldenstrom’s Macroglobulinaemia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Waldenstrom’s Macroglobulinaemia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Waldenstrom’s Macroglobulinaemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Waldenstrom Macroglobulinemia Epidemiology Segmented by-
Total Incident Cases of Waldenstrom Macroglobulinemia (2019–2032)
Gender-specific Cases of Waldenstrom Macroglobulinemia (2019–2032)
Age-specific Cases of Waldenstrom Macroglobulinemia (2019–2032)
Gene Mutations in Waldenstrom Macroglobulinemia (2019–2032)
Waldenstrom’s Macroglobulinaemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Waldenstrom’s Macroglobulinaemia market or expected to be launched during the study period. The analysis covers the Waldenstrom’s Macroglobulinaemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Waldenstrom’s Macroglobulinaemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Waldenstrom’s Macroglobulinaemia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/waldenstrom-macroglobulinemia-market
Waldenstrom’s Macroglobulinaemia Therapeutics Analysis
The U.S. Food and Drug Administration (FDA) has approved the use of ibrutinib and zanubrutinib for Waldenstrom macroglobulinemia. Traditional chemotherapeutic agents, particularly chlorambucil (Leukeran), cyclophosphamide (Cytoxan) and/or melphalan (Alkeran) either as single agents or in combination with others, have been used in the management of this disease for over 40 years but are not commonly used today. The monoclonal antibody rituximab has been found to be effective.
Several major pharma and biotech companies are developing therapies for Waldenstrom’s Macroglobulinaemia to improve the treatment scenario further. Currently, Roche is leading the therapeutics market with its Waldenstrom’s Macroglobulinaemia drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Waldenstrom Macroglobulinemia Therapeutics Market Include:
Amgen
Abbvie
Roche
Bristol-Myers Squibb
Mavorixafor
Loxo Oncology
TransThera Sciences
X4 Pharmaceuticals
Cellectar Biosciences
And Many Others
Waldenstrom’s Macroglobulinaemia Drugs Covered in the Report Include:
Obinutuzumab : Roche
ABT199: Abbvie
LOXO-305: Loxo Oncology
Mavorixafor: X4 Pharmaceuticals
CLR 131: Cellectar Biosciences
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/waldenstrom-macroglobulinemia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Waldenstrom’s Macroglobulinaemia Competitive Intelligence Analysis
4. Waldenstrom’s Macroglobulinaemia Market Overview at a Glance
5. Waldenstrom’s Macroglobulinaemia Disease Background and Overview
6. Waldenstrom’s Macroglobulinaemia Patient Journey
7. Waldenstrom’s Macroglobulinaemia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Waldenstrom’s Macroglobulinaemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Waldenstrom’s Macroglobulinaemia Unmet Needs
10. Key Endpoints of Waldenstrom’s Macroglobulinaemia Treatment
11. Waldenstrom’s Macroglobulinaemia Marketed Products
12. Waldenstrom’s Macroglobulinaemia Emerging Drugs and Latest Therapeutic Advances
13. Waldenstrom’s Macroglobulinaemia Seven Major Market Analysis
14. Attribute Analysis
15. Waldenstrom’s Macroglobulinaemia Market Outlook (In US, EU5, and Japan)
16. Waldenstrom’s Macroglobulinaemia Access and Reimbursement Overview
17. KOL Views on the Waldenstrom’s Macroglobulinaemia Market
18. Waldenstrom’s Macroglobulinaemia Market Drivers
19. Waldenstrom’s Macroglobulinaemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
Waldenstrom’s Macroglobulinaemia Pipeline Insight
“Waldenstrom’s Macroglobulinaemia Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ drugs in Waldenstrom’s Macroglobulinaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by type, stage, route of administration, and molecule type.
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
